Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors

Urology

Volumn 50, Issue 6, 1997, Pages 882-887

  Ellis, William J ^a   Blumenstein, Brent A ^b   Ishak, Laura M ^b   Enfield, David L ^b   Sarosdy, Michael F ^b   Hudson, M'liss A ^b   Soloway, Mark S ^b   DeVere White, Ralph ^b   Sheinfeld, Joel ^b   Jarowenko, Mark V ^b   Schellhammer, Paul F ^b   Schervish, Ed W ^b   Patel, Jay V ^b   Chodak, Gerald W ^b   Lamm, Donald L ^b   Johnson, Robert D ^b   Henderson, Mary ^b   Adams, George ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINE CYTOLOGY;

ADULT; ANTIGENS, NEOPLASM; CONFIDENCE INTERVALS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LATEX FIXATION TESTS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; URINARY BLADDER NEOPLASMS; URINE; WASHINGTON;

EID: 0031464067     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00508-6     Document Type: Article

References (14)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Mostofi FK, Sobin LH, and Torloni H: Histological typing of urinary bladder tumors. WHO International Histological Classification of Tumors. World Health Organization, 1973, pp 9-35.
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Haferman MD, and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol 135: 1083-1086, 1983.
4. Torti FM, and Lum BL: The biology and treatment of superficial bladder cancer. J Clin Oncol 2: 505-531, 1984.
5. Fitzpatrick JM, West AB, Butler MR, Lane V, and O'Flynn JD: Superficial bladder tumors; the importance of recurrence pattern following initial resection. J Urol 135: 920-922, 1986.
6. Abel PD: Follow-up of patients with superficial transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 72: 135-142, 1993.
7. Murphy WM, Crabtree WN, and Jukkola AF: The diagnostic value of urine versus bladder washing in patients with bladder cancer. J Urol 126: 320-322, 1981.
8. Kinders R, Jones T, Root R, Murchison H, Bruce C, Williams L, and Hass GM: Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 157(suppl): 28, 1997.
9. Kinders R, Root R, Jones T, Bruce CL, and Hass GM: Complement factor H-related proteins are expressed in bladder cancers. Proceedings of the 88th Annual Meeting of the American Association of Cancer Research. Am Assoc Cancer Res 38: 29, 1997.
10. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, and Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379-384, 1995.
11. Whitmore WF Jr: Bladder cancer: an overview. CA Cancer J Clin 38: 213-223, 1988.
12. Austyn JM, and Wood KJ: Principles of Cellular and Molecular Immunology. Oxford, Oxford University Press, 1993, pp 522-554.
13. D'Hallewin M, and Baert L: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 155: 475-476, 1996.
14. Leyh H, Hall R, Mazeman E, and Blumenstein BA: Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the blader. Urology 50: 49-53, 1997.